Navigation Links
A 'neurosteroid' found to prevent brain injury caused by HIV/AIDS
Date:1/31/2013

Bethesda, MDA team of scientists from Canada, Thailand and Morocco have found that DHEA-S may prevent neurocognitive impairment that affects a significant percentage of AIDS patients. In a report appearing in the February 2013 issue of The FASEB Journal, they describe how a network of steroid molecules found in the brain, termed "neurosteroids," is disrupted during HIV infection leading to brain damage. This suggests that treatment with one of these steroid molecules, called DHEA-S, may offset the disruption caused by the virus to prevent or reduce brain damage.

"From these studies, we have gained a better understanding of how HIV injures the brain during AIDS, together with developing a new treatment approach for the resulting neurological disabilities arising from HIV/AIDS," said Christopher Power, M.D., co-author of this study from the Department of Medicine at the Medical Research Centre at the University of Alberta in Edmonton, Canada.

To make their discovery, Power and colleagues initially found that neurosteroid enzyme levels were suppressed in the brains of people with HIV/AIDS and that a neurosteroid molecule, DHEA-S, prevented damage to cultured brain cells (neurons) caused by HIV. Then, using an animal model of AIDS, they showed that treatment with DHEA-S prevented neuronal damage in the brain by reducing the adverse effects of HIV. Neurosteroids have already been proposed as treatments for epilepsy, head injury, post-traumatic stress disorder and depression, and these findings extend the potential treatment applications for neurosteroid-related molecules.

"Most people know that AIDS wreaks total havoc on our immune systems," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal, "but far fewer people know that the disease can also lead to noticeable brain damage. This research study offers an explanation why this occurs as well as a possible solution for preventing it. The next steps, of course, involve looking into whether or not people will benefit from some form of DHEA-S treatment."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Brainwave "Balancing" Research Receives $1 Million Grant From The Susanne Marcus Collins Foundation, Inc.
2. Damon Runyon Cancer Research Foundation grants prestigious awards to 17 young scientists
3. Ovarian tumor, with teeth and a bone fragment inside, found in a Roman-age skeleton
4. Previous unknown fox species found
5. Antibacterial agent used in common soaps found in increasing amounts in freshwater lakes
6. Paradise found for Latin Americas largest land mammal
7. Climate change to profoundly affect the Midwest in coming decades
8. Rare form of active jumping genes found in mammals
9. 2 new species of orchid found in Cuba
10. A new type of nerve cell found in the brain
11. Cartenoids found to reduce hip fracture risk in lean men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2019)... (PRWEB) , ... April 17, 2019 , ... USDM Life ... USDM, will deliver a presentation on solutions for Creating a Sustainable Global UDI Compliance ... include the following insights:, , What device manufacturers did to ...
(Date:4/12/2019)... ... April 11, 2019 , ... Neal O’Farrell is one of the first generation ... is executive director of the consumer advocacy non-profit the Identity Theft Council as well ... of the Federal Communications Commission’s Cybersecurity Roundtable and is currently a fellow of the ...
(Date:4/5/2019)... ... 2019 , ... PI’s new L-505 linear translation ... microns resolution, respectively. The new design allows for very compact multi-axis assemblies, at ... with linear encoders and low-friction ball-screws to simple open-loop stepper motors. , ...
Breaking Biology News(10 mins):
(Date:4/8/2019)... ... April 08, 2019 , ... US Capital Global ... $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”). ... Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to begin ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific Diagnostics announced today ... with a second stage of funding for Specific’s Reveal™ rapid antibiotic susceptibility test ... of the $1.7 million already awarded by CARB-X. The additional $1.7M will enable ...
(Date:3/23/2019)... , ... March 22, 2019 , ... ... collection, and analysis to a team of researchers at Nnamdi Azikiwe University in ... Dr. Nneka R. Agbokoba, PhD, of the Department of Medical Laboratory Sciences and ...
(Date:3/19/2019)... ... ... was nine years old when he injured both of his cruciate ligaments. On top ... to experience problems with his mobility. According to his owners, he could barely walk ... couch. , His owners, devastated at the sight of Bogey in so much pain and ...
Breaking Biology Technology: